insulin glargine biosimilar Basaglar
Selected indexed studies
- The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn. (J Diabetes Sci Technol, 2023) [PMID:34971335]
- [New Insulins for Type 1 Diabetes treatment]. (Andes Pediatr, 2023) [PMID:37909930]
- The price paradox of biosimilar-like long-acting insulin. (Am J Manag Care, 2022) [PMID:36374658]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn. (2023) pubmed
- [New Insulins for Type 1 Diabetes treatment]. (2023) pubmed
- The price paradox of biosimilar-like long-acting insulin. (2022) pubmed
- Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation. (2025) pubmed
- Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX). (2025) pubmed
- [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. (2018) pubmed
- Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia. (2022) pubmed
- Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine. (2024) pubmed
- Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR(®)/ABASAGLAR(®)) approved in the European Union. (2017) pubmed
- Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study. (2025) pubmed